Macular Degeneration Clinical Trial
Official title:
FOCUS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMD
Verified date | January 2024 |
Source | Gyroscope Therapeutics Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open label first in human Phase I/II multicentre study of GT005 in subjects with Macular Atrophy due to AMD
Status | Active, not recruiting |
Enrollment | 56 |
Est. completion date | June 28, 2024 |
Est. primary completion date | June 28, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years and older |
Eligibility | Inclusion Criteria: 1. Able and willing to give consent to study participation 2. Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, and a diagnosis of AMD in the contralateral eye (except if the subject is monocular) 3. Cohorts 1 to 6: GA lesion(s) total size in the study eye must be =1.25mm2 and =17.5mm2. Cohort 7: GA lesion(s) total size in the study eye must be =1.25mm2 4. GA lesion(s) in the study eye must reside completely within the FAF fundus image 5. Cohorts 1 to 3: BCVA of =50 letters (6/36 Snellen acuity equivalent or worse) using ETDRS charts in the study eye Cohorts 4 to 7: BCVA of =24 letters (6/95 and 20/320 Snellen acuity equivalent or better) using ETDRS charts in the study eye 6. Aged =55 years 7. Able to attend all study visits and complete the study procedures 8. Women of child-bearing potential need to have a negative urine pregnancy test within two weeks prior to receiving the drug. A pregnancy test is not required for postmenopausal women (defined as being at least 12 consecutive months without menses) or those surgically sterilised (those having a bilateral tubal ligation/bilateral salpingectomy, bilateral tubal occlusive procedure, hysterectomy, or bilateral oophorectomy) Exclusion Criteria: 1. Have evidence or history of Choroidal Neovascularisation (CNV) in the study eye. Subjects are permitted to have CNV in the fellow eye defined as either: 1. Non-exudative/sub-clinical fellow eye CNV identified at screening, or 2. Known history of fellow eye CNV with either =2 years since diagnosis or with no active treatment required in 6 months prior to screening 2. Presence of moderate/severe non-proliferative diabetic retinopathy or worse in the study eye 3. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the study eye 4. History of intraocular surgery in the study eye within 12 weeks prior to Screening (Visit 1). Yttrium aluminum garnet capsulotomy is permitted if performed >10 weeks prior to Visit 1 5. Have clinically significant cataract that may require surgery during the study period in the study eye 6. Presence of moderate to severe glaucomatous optic neuropathy in the study eye; uncontrolled IOP despite the use of more than two topical agents; a history of glaucoma-filtering or valve surgery is also excluded 7. Axial myopia of greater than -8 diopters in the study eye 8. Have received any investigational product for the treatment of GA within the past 6 months or 5 half-lives (whichever is longer), other than nutritional supplements such as the Age-Related Eye Disease Study (AREDS) formula 9. Have received a gene or cell therapy at any time 10. Have a contraindication to the specified protocol corticosteroid regimen 11. Are unwilling to use two forms of contraception (one of which being a barrier method) for 90 days post-dosing, if relevant 12. Active malignancy within the past 12 months, except for: Appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with a stable prostate-specific antigen (PSA) =12 months 13. Have any other significant ocular or non-ocular medical or psychiatric condition which, in the opinion of the Investigator, may either put the subject at risk or may influence the results of the study 14. Cohorts 5 to 7 only: presence of metallic objects or implanted stimulator devices in or near the head, including cochlear implants, deep brain stimulators, vagus nerve stimulators, and other implanted electrodes or stimulators |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Bristol Eye Hospital | Bristol | |
United Kingdom | Moorfields Eye Hospital | London | |
United Kingdom | Retina Clinic London | London | |
United Kingdom | Manchester Eye Hospital | Manchester | |
United Kingdom | Oxford University Hospital | Oxford | |
United Kingdom | Sunderland Eye Infirmary | Sunderland | |
United States | Ophthalamic Consultants of Boston (OCB) | Boston | Massachusetts |
United States | Pepose Vision Institute | Chesterfield | Missouri |
United States | Cincinnati Eye Institute | Cincinnati | Ohio |
United States | Midwest Eye Institute | Indianapolis | Indiana |
United States | Mid-Atlantic Retina | Philadelphia | Pennsylvania |
United States | Sierra Eye Associates | Reno | Nevada |
United States | Wolfe Eye Clinic | West Des Moines | Iowa |
Lead Sponsor | Collaborator |
---|---|
Gyroscope Therapeutics Limited | Novartis Pharmaceuticals |
United States, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of ocular and non-ocular Treatment Emergent AEs (TEAEs) and Treatment-Emergent Serious AEs (TESAEs) Severe Adverse Events (TEAE/TESAE) | Proportion of patients with TEAEs/TESAEs after subretinal injection of GT005 | 240 weeks | |
Secondary | Long-term safety of GT005 at 3 doses | Incidence of ocular and non-ocular treatment-emergent AEs (TEAEs) and treatment-emergent serious AEs (TESAEs) up to 240 weeks | 240 weeks | |
Secondary | Visual Acuity | Change from baseline in BCVA (Best Corrected Visual Acuity) and LLVA (Low Luminance Visual Acuity) score via ETDRS (Early Treatment Diabetic Retinopathy Study) chart | 240 weeks | |
Secondary | Macular Sensitivity | Change from baseline in macular sensitivity as assessed by mesopic Microperimetry | 240 weeks | |
Secondary | Geographic Atrophy | Change from baseline in GA size as assessed by fundus autofluorescence | 240 weeks | |
Secondary | Rate of successful delivery of Balanced Salt Solution (BSS) or BSS PLUS to the subretinal space (US only) | Proportion of subjects with successful delivery of BSS or BSS PLUS to subretinal space | Day 1 | |
Secondary | Rate of successful delivery of GT005 to the subretinal space (US only) | Proportion of subjects with successful delivery of GT005 to subretinal space | Day 1 | |
Secondary | Incidence of device-related AEs and SAEs (US only) | Proportion of subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Completed |
NCT02540954 -
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
|
Phase 3 | |
Completed |
NCT00385333 -
Metabolic Mapping to Measure Retinal Metabolism
|
Phase 2 | |
Completed |
NCT02510794 -
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02181504 -
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Terminated |
NCT02228304 -
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01204541 -
A Single-Center Pilot Study to Assess Macular Function
|
N/A | |
Completed |
NCT00769392 -
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
|
N/A | |
Completed |
NCT00533520 -
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
|
Phase 4 | |
Withdrawn |
NCT00538538 -
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
|
Phase 1 | |
Completed |
NCT00536016 -
A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
|
Phase 1 | |
Terminated |
NCT00403442 -
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
|
Phase 1 | |
Recruiting |
NCT00157976 -
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
|
Phase 3 | |
Completed |
NCT00242580 -
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
|
Phase 3 | |
Completed |
NCT00239928 -
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00211458 -
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
|
Phase 2 | |
Completed |
NCT00095433 -
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
|
Phase 3 | |
Completed |
NCT00006202 -
Lutein for Age-Related Macular Degeneration
|
Phase 2 |